人福医药集团股份公司 关于控股股东重整案重整计划获得法院批准的公告

Core Viewpoint - The court has approved the restructuring plan of Wuhan Contemporary Technology Industry Group Co., Ltd., which is the controlling shareholder of Renfu Pharmaceutical Group Co., Ltd. This approval will lead to a potential change in the controlling shareholder and actual controller of the company [8][19]. Group 1: Restructuring Approval - The Wuhan Intermediate People's Court approved the restructuring plan of Wuhan Contemporary Technology on April 25, 2025, and terminated the restructuring process [8][19]. - The restructuring plan was supported by various creditor groups, meeting the legal requirements for approval [2][3]. Group 2: Shareholder Changes - Following the restructuring, the controlling shareholder of Renfu Pharmaceutical may change from Wuhan Contemporary Technology to招商生命科技（武汉）有限公司 (Zhaoshang Life Technology) [8][12]. - The restructuring plan involves Zhaoshang Life Technology controlling 386,767,393 shares, representing 23.70% of the total share capital of Renfu Pharmaceutical [12][19]. Group 3: Future Steps - The completion of the equity change requires several steps, including the transfer of shares and the restructuring of the board of directors [10][20]. - The restructuring plan includes the establishment of a trust plan and a limited partnership to manage the shares effectively [12][15].